Autopsy report · NCT05921760
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Cause of deathSafety
“The sponsor decided to terminate the study during the safety lead-in phase.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Servier Bio-Innovation LLC
- Sponsor type
- Industry
- Conditions
- IDH1-mutant Cholangiocarcinoma
- Interventions
- Ivosidenib; Nivolumab; Ipilimumab
- Participants
- 7
- Sites
- 5
- Countries
- United Kingdom, United States
Trials that died the same way
- Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
“Sponsor decided to terminate the study” - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
“The sponsor decided to terminate the study early” - Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
“The Sponsor chose to terminate this study for commercial reasons.” - Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
“Sponsor decision to terminate the study” - the Health Crisis at the Healthcare Professionals, Careers and Non-careers, a Month After the Containment Period
“the sponsor decided to stop the study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.